← All trials
NCT05459532
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 12, 2022
- Primary completion
- Jul 31, 2024
- Completion date
- Jul 31, 2027
- First posted
- Jul 15, 2022
- Last posted
- Aug 16, 2022
- Enrollment
- 4000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of the WitwatersrandLead sponsor
- University of the WitwatersrandReponsible party - principal investigator
- University of the WitwatersrandStudy director
- Bill and Melinda Gates FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.